Health
CanSino to start Phase III trial of COVID-19 vaccine in Saudi – The Jakarta Post – Jakarta Post
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China’s CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China’s CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
Last month, CanSino’s co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV.
The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body…
-
Noosa News23 hours agoTop chefs rally for Noosa Reds farmers Pete and Dory
-
Noosa News15 hours agoTerrifying break-in at childcare centre on Sunshine Coast ends with death of man
-
Business21 hours agoThis ASX healthcare stock could be a buy low bargain
-
Business19 hours agoprofit up 24%, outlook strong